Results 21 to 30 of about 51,092 (200)
p13 from group II baculoviruses is a killing-associated gene [PDF]
p13 gene was first described in Leucania separata multinuclearpolyhedrosis virus (Ls-p13) several years ago, but the functionof P13 protein has not been experimentally investigated todate.
Yipeng Qi
doaj +1 more source
Comparative effectiveness of the biosimilar CT-P13
The first biosimilar infliximab, CT-P13 (infliximab-dyyb) has been used for the treatment of inflammatory diseases for 4 years. CT-P13 has highly similar efficacy and safety profiles with a lower price than the originator infliximab and has been approved
Dae Hyun Yoo
core +3 more sources
Stenotrophomonas maltophilia strain P13 was isolated from the Kanchengayao glacier's accumulation zone. A comprehensive study was done on this strain as it produced protease enzyme and thus having industrial potential.
Mingma Thundu Sherpa +3 more
doaj +1 more source
A novel three-colour fluorescence in situ hybridization approach for the detection of t(7;12)(q36;p13) in acute myeloid leukaemia reveals new cryptic three way translocation t(7;12;16) [PDF]
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).The t(7;12)(q36;p13 ...
Vetter, M +15 more
core +1 more source
Background In our previous study, a venom-based peptide named Gonearrestide (also named P13) was identified and demonstrated with an effective inhibition in the proliferation of colon cancer cells.
Rui Ma +5 more
doaj +1 more source
The biosimilar concept is now well established. Clinical data accumulated pre- and post-approval have supported biosimilar uptake, in turn stimulating competition in the biologics market and increasing patient access to biologics. Following technological
HoUng Kim +16 more
doaj +1 more source
Review on t(1;19)(p13;p13.1), with data on ...
Al Bahar, Soad, Zamecnikova, Adriana
core +1 more source
Background We aim to compare the real-life direct and indirect costs of switching patients from intravenous to subcutaneous (SC) CT-P13, an infliximab biosimilar, in a tertiary UK Inflammatory Bowel Disease (IBD) centre.Methods All adult patients with ...
Alaa Alakkari +6 more
doaj +1 more source

